Biovala - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,030 | 550 | 524 | 3,722 | 12,117 | 14,095 | 12,057 | 12,281 |
| Profit before tax | -733 | -512 | -1,400 | 425 | 6,423 | 3,780 | -5,734 | -20,866 |
| Net profit | -733 | -512 | -1,400 | 425 | 6,236 | 3,590 | -5,734 | -20,866 |
| Equity | 0 | 512 | -4,687 | -4,261 | 1,973 | 5,563 | -171 | -21,037 |
| Liabilities | - | - | - | - | 7,255 | 7,837 | 9,109 | 26,369 |
| Non-current assets | 0 | 0 | 0 | 1,682 | 2,529 | 5,866 | 3,384 | 1,698 |
| Current assets | 0 | 1,268 | 852 | 116,959 | 178,268 | 109,173 | 50,124 | 3,634 |
| Total assets | 0 | 1,268 | 852 | 118,641 | 180,797 | 115,039 | 53,508 | 5,332 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 5,729 | 2,434 | 904 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -25.9% | -46.6% | -4.7% | +610.3% | +225.6% | +16.3% | -14.5% | +1.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | -40.4% | -164.3% | 0.4% | 3.4% | 3.1% | -10.7% | -391.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | -100.0% | - | - | 316.1% | 64.5% | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -71.2% | -93.1% | -267.2% | 11.4% | 51.5% | 25.5% | -47.6% | -169.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -71.2% | -93.1% | -267.2% | 11.4% | 53.0% | 26.8% | -47.6% | -169.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 3.7 | 1.4 | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | 3,722 | 6,924 | 12,081 | 12,057 | 12,281 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biovala - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-12-01 | 2022-12-07 | 74.87 |
| 2022-11-30 | 2022-11-30 | 23.92 |
| 2022-08-02 | 2022-08-08 | 23.92 |
Biovala - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-01-01 | 2026-01-24 | 0.01 |
| 2025-08-22 | 2025-08-22 | 0.39 |
| 2025-07-30 | 2025-08-21 | 0.28 |
| 2025-07-28 | 2025-07-29 | 242.9 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biovala, MB (company code 303326367) is a small partnership engaged in research and development in technical sciences. In 2025, revenue was €12.3K, slightly above 2024 (€12.1K) and below 2023 (€14.1K), indicating a relatively stable but modest turnover base over the last three years. The company recorded a net loss of €20.9K in 2025, after a €5.7K loss in 2024 and a €3.6K profit in 2023, showing a clear deterioration in profitability. The 2025 profit margin was -169.9%, reflecting losses far exceeding revenue. The balance sheet also weakened substantially in 2025: total assets declined to €5.3K from €53.5K in 2024 and €115.0K in 2023, while equity moved deeper into negative territory at -€21.0K. Liabilities rose to €26.4K, with short-term assets at €3.6K and long-term assets at €1.7K. Revenue per employee was €12.3K. Given the negative equity position and very small asset base, return and leverage ratios should be interpreted with caution.